When PT, ice, and rest aren't enough — the physician-supervised peptide option for stubborn soft-tissue recovery. Two peptides prescribed together: one builds new blood supply into damaged tissue, the other moves the cells that rebuild it.
We ask about your injury history, current meds, and what you've already tried.
If you're not a fit, you don't pay.
BPC-157 builds new blood vessels into damaged tissue, TB-500 moves the cells that rebuild it.
503A pharmacy.
BPC-157 preclinical: accelerated Achilles tendon-to-bone healing in rats (Krivic et al., 2008), improved muscle crush injury recovery in rats (Pevec et al., 2010), protected gut lining in multiple rod
In animal studies, BPC-157 increased the growth of new blood vessels into injured tendon, muscle, and gut tissue (Sikiric et al., 2018, Journal of Physiology-Paris). More blood supply means more oxygen and nutrients reaching the part you injured.
Thymosin beta-4 binds to actin, the scaffolding inside your cells. In preclinical models it helped cells migrate to the site of injury and reduced scar tissue formation (Goldstein et al., 2012, Annals of the NY Academy of Sciences).
One builds the road. The other moves the trucks down it. In preclinical work the two have been studied separately — ArgoMD's clinicians prescribe them together based on shared mechanism, not on combined clinical trials.
Important information about Wolverine (BPC-157 / TB-500) safety and side effects.
Yes. Both BPC-157 and TB-500 are on the World Anti-Doping Agency prohibited list. If you compete in a tested sport, do not use this stack.
No. Neither peptide is FDA approved. These are compounded medications under Section 503A.
Yes. The FDA placed BPC-157 on the 503A Category 2 list, and TB-500 / thymosin beta-4 is in the same regulatory crosshairs. Many pharmacies have paused compounding them. ArgoMD's pharmacy partner compounds these only when actively permitted under their current legal interpretation. Verify the current FDA status yourself — search "FDA 503A Category 2 bulk drug substances." If access changes, we notify you in writing and do not auto-bill you into a prescription we cannot fill.
503A allows licensed pharmacies to compound for an individual patient with a valid prescription. Every order requires a consultation and a script.
Most commonly reported: injection site irritation, transient fatigue, light-headedness. Long-term safety data in humans is limited.
There's no outcome guarantee. We offer a clinical follow-up at week 4 to reassess.
Real reviews from verified ArgoMD patients.
Started Wolverine (BPC-157 / TB-500) for recovery after a shoulder injury. Within weeks I noticed reduced pain and faster healing than my PT expected. Impressed.
As someone who trains hard, Wolverine (BPC-157 / TB-500) has been a game changer for recovery. Less soreness, faster return to training, and my joints feel better overall.
My physician at ArgoMD recommended Wolverine (BPC-157 / TB-500) as part of my optimization protocol. The quality is excellent and the results speak for themselves.
Your health and safety are our top priorities.